Kristine Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristine Wong has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Kartik Sehgal
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
71 shared publications - Glenn J. Hanna
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
46 shared publications - Robert I. Haddad
Dana-Farber Cancer Institute, Boston, MA, USA
46 shared publications - Justine A. Barletta
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
28 shared publications - Vickie Y. Jo
Brigham and Women’s Hospital, Harvard Medical School
28 shared publications - Erik K. Alexander
Brigham Education Institute Brigham and Women's Hospital Boston Massachusetts USA
27 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Phase I Trial and Biomarker Analysis of Buparlisib with Weekly Cisplatin and Radiotherapy in High-risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Purpose: To determine the maximum tolerated dose (MTD) of the pan–class I PI3K inhibitor buparlisib (B) in combination with weekly cisplatin and radiotherapy (RT) among patients with locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) and tobacco history. Patients and Methods: Patients with stage III/IV LA-SCCHN [American Joint Committee on Cancer (AJCC), Seventh Edition] and >10 pack-year tobacco use history were enrolled. Patients received B during a 2-week run-in phase and during chemoradiotherapy (CRT) consisting of standard 70 Gy of RT plus weekly cisplatin. An exploratory analysis of genomic sequencing was performed on biopsy specimens. Results: Twenty-three patients were enrolled {n = 17 at the MTD [B 40 mg daily and cisplatin (CDDP) 30 mg/m2/week]}. Ninety-one percent (21/23) had stage IV disease. Human papillomavirus (HPV) was detected in 15 of 18 cases with oral/oropharyngeal disease. The median follow-up was 23 months. Recurrence was detected in five patients among whom four had evaluable tumor samples. Fifty-percent (2/4) of patients with evaluable tumor samples were characterized by activation of the PI3K pathway. In five patients whose disease responded during the 2-week run-in phase with B alone, 3 of 4 with sequencing data showed loss-of-function mutations in either tumor necrosis factor receptor–associated factor 3 (TRAF3) or cylindromatosis lysine deubiquitinase (CYLD). Preclinical studies with mutations in TRAF3 or CYLD modeled via CRISPR/Cas9 knockout in HPV+ SCCHN cells demonstrate that loss of TRAF3 or CYLD may sensitize SCCHN cell lines to PI3K through mechanisms other than blocking the NF-κB pathway. Conclusions: Low-dose B with CRT was feasible and active in this high-risk cohort, although escalation to the standard weekly cisplatin dose of 40 mg/m2 was not possible. Our data suggest that TRAF3/CYLD-mutant SCCHN may be susceptible to PI3K inhibition with B, whereas PI3K pathway activation seemed to be associated with poor outcomes in this limited dataset.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessPhase I Trial and Biomarker Analysis of Buparlisib with Weekly Cisplatin and Radiotherapy in High-risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Purpose: To determine the maximum tolerated dose (MTD) of the pan–class I PI3K inhibitor buparlisib (B) in combination with weekly cisplatin and radiotherapy (RT) among patients with locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) and tobacco history. Patients and Methods: Patients with stage III/IV LA-SCCHN [American Joint Committee on Cancer (AJCC), Seventh Edition] and >10 pack-year tobacco use history were enrolled. Patients received B during a 2-week run-in phase and during chemoradiotherapy (CRT) consisting of standard 70 Gy of RT plus weekly cisplatin. An exploratory analysis of genomic sequencing was performed on biopsy specimens. Results: Twenty-three patients were enrolled {n = 17 at the MTD [B 40 mg daily and cisplatin (CDDP) 30 mg/m2/week]}. Ninety-one percent (21/23) had stage IV disease. Human papillomavirus (HPV) was detected in 15 of 18 cases with oral/oropharyngeal disease. The median follow-up was 23 months. Recurrence was detected in five patients among whom four had evaluable tumor samples. Fifty-percent (2/4) of patients with evaluable tumor samples were characterized by activation of the PI3K pathway. In five patients whose disease responded during the 2-week run-in phase with B alone, 3 of 4 with sequencing data showed loss-of-function mutations in either tumor necrosis factor receptor–associated factor 3 (TRAF3) or cylindromatosis lysine deubiquitinase (CYLD). Preclinical studies with mutations in TRAF3 or CYLD modeled via CRISPR/Cas9 knockout in HPV+ SCCHN cells demonstrate that loss of TRAF3 or CYLD may sensitize SCCHN cell lines to PI3K through mechanisms other than blocking the NF-κB pathway. Conclusions: Low-dose B with CRT was feasible and active in this high-risk cohort, although escalation to the standard weekly cisplatin dose of 40 mg/m2 was not possible. Our data suggest that TRAF3/CYLD-mutant SCCHN may be susceptible to PI3K inhibition with B, whereas PI3K pathway activation seemed to be associated with poor outcomes in this limited dataset.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Eligible and completed plasma TTMV tests at each study time point
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Eligible and completed plasma TTMV tests at each study time point
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Number of subjects eligible for and with completed TTMV testing at each study time point
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Number of subjects eligible for and with completed TTMV testing at each study time point
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Representativeness of study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Representativeness of study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Clinical evaluations performed after detectable surveillance TTMV until diagnosis of recurrence for early true-positive subjects
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Clinical evaluations performed after detectable surveillance TTMV until diagnosis of recurrence for early true-positive subjects
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for subjects with baseline detectable TTMV and HPV16
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for subjects with baseline detectable TTMV and HPV16
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for subjects with baseline TTMV>200 and HPV16
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for subjects with baseline TTMV>200 and HPV16
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Histogram of tests per patient
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Histogram of tests per patient
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for total study population
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue–Modified Viral HPV DNA
Test performance metrics for total study population